178 related articles for article (PubMed ID: 35305722)
1. Understanding the activating mechanism of the immune system against COVID-19 by Traditional Indian Medicine: Network pharmacology approach.
Thirumal Kumar D; Shree Devi MS; Udhaya Kumar S; Sherlin A; Mathew A; Lakshmipriya M; Sathiyarajeswaran P; Gnanasambandan R; Siva R; Magesh R; George Priya Doss C
Adv Protein Chem Struct Biol; 2022; 129():275-379. PubMed ID: 35305722
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the active constituents of Nilavembu Kudineer for viral replication inhibition against SARS-CoV-2: An approach to targeting RNA-dependent RNA polymerase (RdRp).
Kuriakose A; Nair B; Abdelgawad MA; Adewum AT; Soliman MES; Mathew B; Nath LR
J Food Biochem; 2022 Nov; 46(11):e14367. PubMed ID: 35994404
[TBL] [Abstract][Full Text] [Related]
3. In Silico computational screening of Kabasura Kudineer - Official Siddha Formulation and JACOM against SARS-CoV-2 spike protein.
Kiran G; Karthik L; Shree Devi MS; Sathiyarajeswaran P; Kanakavalli K; Kumar KM; Ramesh Kumar D
J Ayurveda Integr Med; 2022; 13(1):100324. PubMed ID: 32527713
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of two siddha polyherbal decoctions, Nilavembu Kudineer and Kaba Sura Kudineer, along with standard allopathy treatment in the management of mild to moderate symptomatic COVID-19 patients-a double-blind, placebo-controlled, clinical trial.
Srivastava A; Rengaraju M; Srivastava S; Narayanan V; Gupta V; Upadhayay R; Kumar J; Parameswaran S; KanakavalliKadarkarai ; AarthiVelmurugan
Trials; 2021 Aug; 22(1):570. PubMed ID: 34454572
[TBL] [Abstract][Full Text] [Related]
5. A double blinded placebo controlled comparative clinical trial to evaluate the effectiveness of Siddha medicines, Kaba Sura Kudineer (KSK) & Nilavembu Kudineer (NVK) along with standard Allopathy treatment in the management of symptomatic COVID 19 patients - a structured summary of a study protocol for a randomized controlled trial.
Srivastava A; Rengaraju M; Srivastava S; Narayan V; Gupta V; Upadhayay R
Trials; 2021 Feb; 22(1):130. PubMed ID: 33573696
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of Kabasura Kudineer tablets in the management of asymptomatic and mild cases of COVID-19: A pilot double-blinded, randomized controlled trial.
Khapre M; Pathania M; Saxena V; Omar BJ; Goyal B; Sinha S; Bahurupi Y; Dhamija P
J Ayurveda Integr Med; 2023; 14(4):100777. PubMed ID: 37536025
[TBL] [Abstract][Full Text] [Related]
7. Computational Study on the Inhibitory Effect of Natural Compounds against the SARS-CoV-2 Proteins.
Jayaraj JM; Jothimani M; Palanisamy CP; Pentikäinen OT; Pannipara M; Al-Sehemi AG; Muthusamy K; Gopinath K
Bioinorg Chem Appl; 2022; 2022():8635054. PubMed ID: 35340421
[TBL] [Abstract][Full Text] [Related]
8. Molecular Docking Studies on the Anti-viral Effects of Compounds From Kabasura Kudineer on SARS-CoV-2 3CL
Vincent S; Arokiyaraj S; Saravanan M; Dhanraj M
Front Mol Biosci; 2020; 7():613401. PubMed ID: 33425994
[TBL] [Abstract][Full Text] [Related]
9. Chlorogenic acid, a natural product as potential inhibitor of COVID-19: virtual screening experiment based on network pharmacology and molecular docking.
Wang WX; Zhang YR; Luo SY; Zhang YS; Zhang Y; Tang C
Nat Prod Res; 2022 May; 36(10):2580-2584. PubMed ID: 33769143
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-10 as Covid-19 biomarker targeting KSK and its analogues: Integrated network pharmacology.
V VR; Ramu A; Chinnappan J; Velmurugan P; Pathak R; Pashameah RA; A Oyouni AA; M Al-Amer O; I Alasseiri M; Hamadi A; A Alanazi M; Sathiamoorthi T
PLoS One; 2023; 18(3):e0282263. PubMed ID: 36989283
[TBL] [Abstract][Full Text] [Related]
11. Attitudes, beliefs, and self-use of Kabasura Kudineer among urban and rural population in Tamil Nadu, India: A comparative cross-sectional study.
Bala D
J Family Med Prim Care; 2021 Jan; 10(1):158-166. PubMed ID: 34017720
[TBL] [Abstract][Full Text] [Related]
12. Molecular docking analysis of potential compounds from an Indian medicinal soup "kabasura kudineer" extract with IL-6.
Saleem Basha S; Tripathi D; Koora S; Satyanarayana K; Jayaraman S
Bioinformation; 2020; 17(5):568-572. PubMed ID: 35095231
[TBL] [Abstract][Full Text] [Related]
13. Bioactive Components of
Yuan H; Liu L; Zhou J; Zhang T; Daily JW; Park S
J Med Food; 2022 Apr; 25(4):355-366. PubMed ID: 35438554
[TBL] [Abstract][Full Text] [Related]
14. Investigating the active compounds and mechanism of HuaShi XuanFei formula for prevention and treatment of COVID-19 based on network pharmacology and molecular docking analysis.
Wang J; Ge W; Peng X; Yuan L; He S; Fu X
Mol Divers; 2022 Apr; 26(2):1175-1190. PubMed ID: 34105049
[TBL] [Abstract][Full Text] [Related]
15. Potential effect of Maxing Shigan decoction against coronavirus disease 2019 (COVID-19) revealed by network pharmacology and experimental verification.
Li Y; Chu F; Li P; Johnson N; Li T; Wang Y; An R; Wu D; Chen J; Su Z; Gu X; Ding X
J Ethnopharmacol; 2021 May; 271():113854. PubMed ID: 33513419
[TBL] [Abstract][Full Text] [Related]
16. Exploration of molecular targets and mechanisms of Chinese medicinal formula Acacia Catechu -Scutellariae Radix in the treatment of COVID-19 by a systems pharmacology strategy.
Feng T; Zhang M; Xu Q; Song F; Wang L; Gai S; Tang H; Wang S; Zhou L; Li H
Phytother Res; 2022 Nov; 36(11):4210-4229. PubMed ID: 35859316
[TBL] [Abstract][Full Text] [Related]
17. In silico network pharmacology study on Glycyrrhiza glabra: Analyzing the immune-boosting phytochemical properties of Siddha medicinal plant against COVID-19.
Sekaran K; Karthik A; Varghese RP; Sathiyarajeswaran P; Shree Devi MS; Siva R; George Priya Doss C
Adv Protein Chem Struct Biol; 2024; 138():233-255. PubMed ID: 38220426
[TBL] [Abstract][Full Text] [Related]
18. The efficacy of Siddha Medicine, Kabasura Kudineer (KSK) compared to Vitamin C & Zinc (CZ) supplementation in the management of asymptomatic COVID-19 cases: A structured summary of a study protocol for a randomised controlled trial.
Natarajan S; Anbarasi C; Sathiyarajeswaran P; Manickam P; Geetha S; Kathiravan R; Prathiba P; Pitchiahkumar M; Parthiban P; Kanakavalli K; Balaji P
Trials; 2020 Oct; 21(1):892. PubMed ID: 33109252
[TBL] [Abstract][Full Text] [Related]
19. Network pharmacology and molecular docking analysis on molecular targets and mechanisms of Huashi Baidu formula in the treatment of COVID-19.
Tao Q; Du J; Li X; Zeng J; Tan B; Xu J; Lin W; Chen XL
Drug Dev Ind Pharm; 2020 Aug; 46(8):1345-1353. PubMed ID: 32643448
[TBL] [Abstract][Full Text] [Related]
20. In Silico Identification of Potential Natural Product Inhibitors of Human Proteases Key to SARS-CoV-2 Infection.
Vivek-Ananth RP; Rana A; Rajan N; Biswal HS; Samal A
Molecules; 2020 Aug; 25(17):. PubMed ID: 32842606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
